Shares of China's CanSino Biologics rise as much as 15% on Wednesday afternoon. Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable. 康希诺生物日内走高,一度涨超15%,此前宣布与Aerogen合作开发全球首款吸入式新冠疫苗。 $康希诺生物 (06185.HK)$$康希诺 (688185.SH)$
康希诺股票讨论区
$科兴生物 (SVA.US)$ $复星医药 (02196.HK)$ $复星医药 (600196.SH)$ $康希诺 (688185.SH)$ $康希诺生物 (06185.HK)$ $沃森生物 (300142.SZ)$ $智飞生物 (300122.SZ)$
$康希诺生物 (06185.HK)$ $康希诺 (688185.SH)$
Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.
康希诺生物日内走高,一度涨超15%,此前宣布与Aerogen合作开发全球首款吸入式新冠疫苗。
$康希诺生物 (06185.HK)$ $康希诺 (688185.SH)$
$康希诺 (688185.SH)$
$康希诺 (688185.SH)$
暂无评论